Inactive Instrument

Cell Source Inc Stock OTC Bulletin Board

US15114L1044

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

05-14	Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
04-07	Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).

Employees

Sector

Biotechnology & Medical Research

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	24.41M 21.81M 20.35M 18.48M 34.81M 2.36B 35.07M 245M 95.53M 1.2B 91.64M 89.66M 3.86B	P/E 2023	-2.65x	P/E 2024	-2.49x
Enterprise Value	34.92M 31.2M 29.11M 26.44M 49.8M 3.38B 50.17M 350M 137M 1.72B 131M 128M 5.52B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	80.32%	Yield 2023 *	-	Yield 2024	-

05-14	Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
04-07	Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
04-06	Cell Source, Inc. Auditor Raises 'Going Concern' Doubt	CI
01-14	Cell Source, Inc. announced that it has received $1.5 million in funding	CI
24-11-21	Cell Source, Inc. Shared Positive Interim Results from Its Phase 1/2 First-In-Human Clinical Trial Conducted At the University of Texas Md Anderson Cancer Center	CI
24-11-14	Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-19	Cell Source, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-07-29	Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-06-24	Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-06-23	Cell Source, Inc. Auditor Raises 'Going Concern' Doubt	CI
24-03-21	Cell Source, Inc. announced that it has received $4.76017 million in funding	CI
23-11-09	Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-09-19	Cell Source, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

05-21	Cell Source Presented Its Breakthrough Developments for Mismatched Donor Stem Cell and Organ Transplants and Off-the-shelf CAR-T Cell Therapy at the LD Micro Invitational Conference in Los Angeles This Week	AQ
05-14	Cell Source, Inc. to Present at the LD Micro Invitational XVI	NE
05-14	Cell Source : Quarterly Report for Quarter Ending March 31, 2025 (Form 10-Q)	PU
04-07	Cell Source : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)	PU
22-12-08	Note 2 - Going Concern and Management Plans	AQ

Director	Title	Age	Since
Dennis Brown CHM	Chairman	77	2015-05-17
Darlene Soave BRD	Director/Board Member	82	2021-03-24
George Verstraete BRD	Director/Board Member	72	2022-03-09

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.16%	+4.16%	+49.37%	+94.17%	74.69B
ARGENX SE	+0.46%	-0.97%	+23.51%	+79.34%	58.81B
LONZA GROUP AG	+0.17%	+0.35%	+6.85%	+34.55%	48.45B
REVOLUTION MEDICINES, INC.	+0.50%	-2.14%	+331.33%	+702.20%	42.84B
IQVIA HOLDINGS INC.	-0.72%	-3.99%	+28.50%	+29.94%	42.79B
BEONE MEDICINES AG	+0.34%	-0.52%	+6.56%	+109.35%	41.25B
CELLTRION, INC.	-0.11%	+1.96%	+9.19%	+52.66%	31.13B
BIONTECH SE	-0.50%	-3.10%	-10.19%	-14.35%	24.05B
INSMED INCORPORATED	-3.32%	-10.86%	-37.32%	+316.28%	22.98B
Average	+0.11%	-2.37%	+45.31%	+156.02%	43B
Weighted average by Cap.	+0.67%	-1.80%	+52.38%	+149.38%

Cell Source Inc Stock OTC Bulletin Board

Stocks

US15114L1044

Biotechnology & Medical Research

Valuation: Cell Source Inc

Latest news: Cell Source Inc

Press Releases: Cell Source Inc

Managers and Directors: Cell Source Inc

Bio Therapeutic Drugs

Financials

Company Profile

	2023	2024
Net sales	-	-
Net income	-5.32M -4.75M -4.44M -4.03M -7.59M -515M -7.64M -53.3M -20.83M -262M -19.98M -19.54M -842M	-4.51M -4.03M -3.76M -3.42M -6.44M -437M -6.48M -45.2M -17.66M -222M -16.94M -16.57M -714M
Net Debt	9.27M 8.29M 7.73M 7.02M 13.23M 897M 13.32M 92.9M 36.29M 456M 34.82M 34.06M 1.47B	10.51M 9.39M 8.76M 7.96M 14.99M 1.02B 15.1M 105M 41.12M 517M 39.45M 38.6M 1.66B